PHARMAXIS EUROPE
PharmaPHARMAXIS EUROPE is a pharmaceutical company focused on Ophthalmology. Key products include BRONCHITOL.
PHARMAXIS EUROPE's Key Drugs
PHARMAXIS EUROPE's core commercial portfolio centers on BRONCHITOL, spanning Ophthalmology — its most strategically important drugs approved in the last 15 years.
PHARMAXIS EUROPE's Recent FDA Approvals
New NDA/BLA approvals for PHARMAXIS EUROPE over the last two years — novel drugs only, excluding generics and label supplements.
PHARMAXIS EUROPE's Therapeutic Areas
PHARMAXIS EUROPE's approved drugs and pipeline span 1 therapeutic area, led by Ophthalmology, across 0 biologic and 3 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
PHARMAXIS EUROPE's Top Competitors
PHARMAXIS EUROPE's closest competitors by therapeutic-area and drug-target overlap include Novartis, AbbVie, and OTSUKA ICU MEDCL. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
PHARMAXIS EUROPE Pipeline Snapshot
Active clinical trials for PHARMAXIS EUROPE across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • BRONCHITOL leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Ophthalmology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2010-10-05
- Latest
- 2021-08-13
- Applications
- 2